NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
36 trialsNCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT05296005 2025-02-07
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04183062 2024-11-08
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Phase 2 Withdrawn
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT02451865 2020-07-24
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02182622 2019-06-19
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Phase 1 Withdrawn
NCT03370159 2018-08-01
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1/2 Withdrawn
NCT03343977 2018-07-17
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
University of Kentucky
Phase 1/2 Withdrawn
NCT02793219 2017-10-30
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02793765 2017-10-30
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT01087580 2017-03-03
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT00452920 2016-12-15
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
University of Miami
Phase 1/2 Withdrawn
NCT00598858 2016-12-08
2007-5904
University of California, Irvine
Phase 2 Withdrawn
NCT02083536 2016-08-10
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
University of Miami
Phase 1 Withdrawn
NCT02522910 2016-08-10
An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1/2 Withdrawn
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT02536495 2015-10-30
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT01685489 2015-10-27
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
Phase 1 Withdrawn
NCT00755157 2015-10-07
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
University Hospital of Crete
Phase 2 Withdrawn
NCT01071928 2015-08-19
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT02120118 2015-06-09
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Shin Kong Wu Ho-Su Memorial Hospital
Phase 2 Withdrawn
NCT01562301 2015-06-08
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00313690 2014-05-21
Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer
University of Southern California
Phase 1/2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT00074139 2014-03-05
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01478308 2013-03-06
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00048087 2012-07-31
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00434031 2012-07-30
CETRA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT00811031 2012-07-30
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01229605 2011-12-12
Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer
Tufts Medical Center
Phase 2 Withdrawn
NCT00006261 2010-06-10
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn